Yongchang Zhang

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials

Phase

• Phase 23 trials
• Phase 2/31 trial
• Phase 31 trial

Status

• Not yet recruiting3 trials
• Recruiting3 trials

Lead sponsor

• Hunan Province Tumor Hospital6 trials

Running trials

• Not yet recruiting

  Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

  NCT07001995· Phase 2· Hunan Province Tumor Hospital· Source

  Contact: Yongchang Zhang, MD

• Not yet recruiting

  Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

  NCT06828757· Phase 3· Hunan Province Tumor Hospital· Source

• Not yet recruiting

  Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance

  NCT06634667· Phase 2· Hunan Province Tumor Hospital· Source

  Contact: Yongchang Zhang, MD

• Recruiting

  Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

  NCT04322890· Phase 2· Hunan Province Tumor Hospital· Source

  Contact: Yongchang Zhang, MD

• Recruiting

  Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

  NCT04322617· Phase 2/3· Hunan Province Tumor Hospital· Source

  Contact: Yongchang Zhang, MD

• Recruiting

  Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

  NCT04324164· Hunan Province Tumor Hospital· Source

  Contact: Yongchang Zhang, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer6 recruiting